BDCA1+CD14+ Immunosuppressive Cells in Cancer, a Potential Target?
Thomas J van EeHeleen H Van AckerTom G van OorschotViggo F I Van TendelooEvelien L SmitsGhaith BakdashI Jolanda M de VriesPublished in: Vaccines (2018)
Dendritic cell (DC) vaccines show promising effects in cancer immunotherapy. However, their efficacy is affected by a number of factors, including (1) the quality of the DC vaccine and (2) tumor immune evasion. The recently characterized BDCA1+CD14+ immunosuppressive cells combine both aspects; their presence in DC vaccines may directly hamper vaccine efficacy, whereas, in patients, BDCA1+CD14+ cells may suppress the induced immune response in an antigen-specific manner systemically and at the tumor site. We hypothesize that BDCA1+CD14+ cells are present in a broad spectrum of cancers and demand further investigation to reveal treatment opportunities and/or improvement for DC vaccines. In this review, we summarize the findings on BDCA1+CD14+ cells in solid cancers. In addition, we evaluate the presence of BDCA1+CD14+ cells in leukemic cancers. Preliminary results suggest that the presence of BDCA1+CD14+ cells correlates with clinical features of acute and chronic myeloid leukemia. Future research focusing on the differentiation from monocytes towards BDCA1+CD14+ cells could reveal more about their cell biology and clinical significance. Targeting these cells in cancer patients may improve the outcome of cancer immunotherapy.
Keyphrases
- induced apoptosis
- cell cycle arrest
- immune response
- dendritic cells
- cell death
- squamous cell carcinoma
- signaling pathway
- single cell
- endothelial cells
- risk assessment
- cell proliferation
- hepatitis b virus
- inflammatory response
- newly diagnosed
- genome wide
- bone marrow
- human health
- papillary thyroid
- regulatory t cells
- lymph node metastasis
- young adults
- extracorporeal membrane oxygenation
- mechanical ventilation
- acute respiratory distress syndrome